A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States

Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2020-04, Vol.4 (8), p.1780-1791
Hauptverfasser: Alqemlas, Ibrahim, Shankar, Sneha, Handagama, Winode, Felse, P. Arthur
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1791
container_issue 8
container_start_page 1780
container_title Blood advances
container_volume 4
creator Alqemlas, Ibrahim
Shankar, Sneha
Handagama, Winode
Felse, P. Arthur
description Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified 4700 recall events, 7 reasons for recall, and 144 346 units affected by recalls. Using geospatial mapping of the newly defined county-level recall event density, we discovered hot spots with high prevalence and likelihood of blood product recall events. Distribution patterns and distribution distances of recalled blood products vary significantly between product types. Blood plasma is the most recalled product (87 980 units), and leukocyte-reduced products (34 230 units) are recalled in larger numbers than non-leukocyte-reduced products (8076 units). Donor-related reasons (92 382 units) and sterility deviations (22 408 units) are the major cause of blood product recalls. Monetary loss resulting from blood product recalls is estimated to be $17.9 million, and economic sensitivity tests show that donor-related reasons and sterility deviations contribute most to the overall monetary burden. A total of 2.8 million days was required to resolve recall events, and probabilistic survival time analysis shows that sterility deviations and contamination took longer to resolve because of their systemic effect on blood collection and processing. Our studies demonstrate that better donor screening procedures, rigorous sterility requirements, improved containment methods, and mitigation of recall events in high-prevalence regions will enable a more robust blood supply chain. •Blood product recalls are highly prevalent in certain geographic regions, and distribution patterns vary between product types.•Inadequate donor screening, compromised sterility, and contamination contribute most to the burden of blood products recalls. [Display omitted]
doi_str_mv 10.1182/bloodadvances.2019001024
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7189286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920313690</els_id><sourcerecordid>2396307141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-40624309e3f4c08f599448a080eebc841bc37b5374ad10052004a25742dd2ad63</originalsourceid><addsrcrecordid>eNqFkctuFDEQRS0EIlHILyAvWaSDXz1ub5BCxEuKxAKytqrtamLkaQ-2e6T8Pe5MGMiKla3yubfKdQmhnF1yPoi3Y0zJg9_D7LBcCsYNY5wJ9YycCqVlZ3qpnx_vwpyQ81J-sgbpjeyNeElOpJBKaqNPSb2iLqdSuoKuhjRDpKUu_p6mie4y7iFia3NBfSg1h3FZmQvqYCmtCLOnYbsDV1f8Ya4mSn5phYwOYiw0zLTeIb2dQ0VPv1WoWF6RFxPEgueP5xm5_fjh-_Xn7ubrpy_XVzedU9rUTrGNUJIZlJNybJh6Y5QagA0McXSD4qOTemy_VeA5Y71gTIHotRLeC_AbeUbeHXx3y7hF73CuGaLd5bCFfG8TBPv0ZQ539kfaW80HI4bV4M2jQU6_FizVbkNxGCPMmJZihTQbyTRXvKHDAX1YZ8bp2IYzu-Zmn-Rm_-bWpK__HfMo_JNSA94fAGzL2gfMtriw5uJDW3O1PoX_d_kN7ruwQw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2396307141</pqid></control><display><type>article</type><title>A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Alqemlas, Ibrahim ; Shankar, Sneha ; Handagama, Winode ; Felse, P. Arthur</creator><creatorcontrib>Alqemlas, Ibrahim ; Shankar, Sneha ; Handagama, Winode ; Felse, P. Arthur</creatorcontrib><description>Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified 4700 recall events, 7 reasons for recall, and 144 346 units affected by recalls. Using geospatial mapping of the newly defined county-level recall event density, we discovered hot spots with high prevalence and likelihood of blood product recall events. Distribution patterns and distribution distances of recalled blood products vary significantly between product types. Blood plasma is the most recalled product (87 980 units), and leukocyte-reduced products (34 230 units) are recalled in larger numbers than non-leukocyte-reduced products (8076 units). Donor-related reasons (92 382 units) and sterility deviations (22 408 units) are the major cause of blood product recalls. Monetary loss resulting from blood product recalls is estimated to be $17.9 million, and economic sensitivity tests show that donor-related reasons and sterility deviations contribute most to the overall monetary burden. A total of 2.8 million days was required to resolve recall events, and probabilistic survival time analysis shows that sterility deviations and contamination took longer to resolve because of their systemic effect on blood collection and processing. Our studies demonstrate that better donor screening procedures, rigorous sterility requirements, improved containment methods, and mitigation of recall events in high-prevalence regions will enable a more robust blood supply chain. •Blood product recalls are highly prevalent in certain geographic regions, and distribution patterns vary between product types.•Inadequate donor screening, compromised sterility, and contamination contribute most to the burden of blood products recalls. [Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2019001024</identifier><identifier>PMID: 32343797</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cross-Sectional Studies ; Prevalence ; Product Recalls and Withdrawals ; Transfusion Medicine ; United States - epidemiology ; United States Food and Drug Administration</subject><ispartof>Blood advances, 2020-04, Vol.4 (8), p.1780-1791</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><rights>2020 by The American Society of Hematology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-40624309e3f4c08f599448a080eebc841bc37b5374ad10052004a25742dd2ad63</citedby><cites>FETCH-LOGICAL-c479t-40624309e3f4c08f599448a080eebc841bc37b5374ad10052004a25742dd2ad63</cites><orcidid>0000-0003-0238-2092</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189286/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189286/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32343797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alqemlas, Ibrahim</creatorcontrib><creatorcontrib>Shankar, Sneha</creatorcontrib><creatorcontrib>Handagama, Winode</creatorcontrib><creatorcontrib>Felse, P. Arthur</creatorcontrib><title>A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified 4700 recall events, 7 reasons for recall, and 144 346 units affected by recalls. Using geospatial mapping of the newly defined county-level recall event density, we discovered hot spots with high prevalence and likelihood of blood product recall events. Distribution patterns and distribution distances of recalled blood products vary significantly between product types. Blood plasma is the most recalled product (87 980 units), and leukocyte-reduced products (34 230 units) are recalled in larger numbers than non-leukocyte-reduced products (8076 units). Donor-related reasons (92 382 units) and sterility deviations (22 408 units) are the major cause of blood product recalls. Monetary loss resulting from blood product recalls is estimated to be $17.9 million, and economic sensitivity tests show that donor-related reasons and sterility deviations contribute most to the overall monetary burden. A total of 2.8 million days was required to resolve recall events, and probabilistic survival time analysis shows that sterility deviations and contamination took longer to resolve because of their systemic effect on blood collection and processing. Our studies demonstrate that better donor screening procedures, rigorous sterility requirements, improved containment methods, and mitigation of recall events in high-prevalence regions will enable a more robust blood supply chain. •Blood product recalls are highly prevalent in certain geographic regions, and distribution patterns vary between product types.•Inadequate donor screening, compromised sterility, and contamination contribute most to the burden of blood products recalls. [Display omitted]</description><subject>Cross-Sectional Studies</subject><subject>Prevalence</subject><subject>Product Recalls and Withdrawals</subject><subject>Transfusion Medicine</subject><subject>United States - epidemiology</subject><subject>United States Food and Drug Administration</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctuFDEQRS0EIlHILyAvWaSDXz1ub5BCxEuKxAKytqrtamLkaQ-2e6T8Pe5MGMiKla3yubfKdQmhnF1yPoi3Y0zJg9_D7LBcCsYNY5wJ9YycCqVlZ3qpnx_vwpyQ81J-sgbpjeyNeElOpJBKaqNPSb2iLqdSuoKuhjRDpKUu_p6mie4y7iFia3NBfSg1h3FZmQvqYCmtCLOnYbsDV1f8Ya4mSn5phYwOYiw0zLTeIb2dQ0VPv1WoWF6RFxPEgueP5xm5_fjh-_Xn7ubrpy_XVzedU9rUTrGNUJIZlJNybJh6Y5QagA0McXSD4qOTemy_VeA5Y71gTIHotRLeC_AbeUbeHXx3y7hF73CuGaLd5bCFfG8TBPv0ZQ539kfaW80HI4bV4M2jQU6_FizVbkNxGCPMmJZihTQbyTRXvKHDAX1YZ8bp2IYzu-Zmn-Rm_-bWpK__HfMo_JNSA94fAGzL2gfMtriw5uJDW3O1PoX_d_kN7ruwQw</recordid><startdate>20200428</startdate><enddate>20200428</enddate><creator>Alqemlas, Ibrahim</creator><creator>Shankar, Sneha</creator><creator>Handagama, Winode</creator><creator>Felse, P. Arthur</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0238-2092</orcidid></search><sort><creationdate>20200428</creationdate><title>A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States</title><author>Alqemlas, Ibrahim ; Shankar, Sneha ; Handagama, Winode ; Felse, P. Arthur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-40624309e3f4c08f599448a080eebc841bc37b5374ad10052004a25742dd2ad63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cross-Sectional Studies</topic><topic>Prevalence</topic><topic>Product Recalls and Withdrawals</topic><topic>Transfusion Medicine</topic><topic>United States - epidemiology</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alqemlas, Ibrahim</creatorcontrib><creatorcontrib>Shankar, Sneha</creatorcontrib><creatorcontrib>Handagama, Winode</creatorcontrib><creatorcontrib>Felse, P. Arthur</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alqemlas, Ibrahim</au><au>Shankar, Sneha</au><au>Handagama, Winode</au><au>Felse, P. Arthur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2020-04-28</date><risdate>2020</risdate><volume>4</volume><issue>8</issue><spage>1780</spage><epage>1791</epage><pages>1780-1791</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified 4700 recall events, 7 reasons for recall, and 144 346 units affected by recalls. Using geospatial mapping of the newly defined county-level recall event density, we discovered hot spots with high prevalence and likelihood of blood product recall events. Distribution patterns and distribution distances of recalled blood products vary significantly between product types. Blood plasma is the most recalled product (87 980 units), and leukocyte-reduced products (34 230 units) are recalled in larger numbers than non-leukocyte-reduced products (8076 units). Donor-related reasons (92 382 units) and sterility deviations (22 408 units) are the major cause of blood product recalls. Monetary loss resulting from blood product recalls is estimated to be $17.9 million, and economic sensitivity tests show that donor-related reasons and sterility deviations contribute most to the overall monetary burden. A total of 2.8 million days was required to resolve recall events, and probabilistic survival time analysis shows that sterility deviations and contamination took longer to resolve because of their systemic effect on blood collection and processing. Our studies demonstrate that better donor screening procedures, rigorous sterility requirements, improved containment methods, and mitigation of recall events in high-prevalence regions will enable a more robust blood supply chain. •Blood product recalls are highly prevalent in certain geographic regions, and distribution patterns vary between product types.•Inadequate donor screening, compromised sterility, and contamination contribute most to the burden of blood products recalls. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32343797</pmid><doi>10.1182/bloodadvances.2019001024</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0238-2092</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2473-9529
ispartof Blood advances, 2020-04, Vol.4 (8), p.1780-1791
issn 2473-9529
2473-9537
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7189286
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Cross-Sectional Studies
Prevalence
Product Recalls and Withdrawals
Transfusion Medicine
United States - epidemiology
United States Food and Drug Administration
title A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20cross-sectional%20study%20of%20prevalence,%20distribution,%20cause,%20and%20impact%20of%20blood%20product%20recalls%20in%20the%20United%20States&rft.jtitle=Blood%20advances&rft.au=Alqemlas,%20Ibrahim&rft.date=2020-04-28&rft.volume=4&rft.issue=8&rft.spage=1780&rft.epage=1791&rft.pages=1780-1791&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2019001024&rft_dat=%3Cproquest_pubme%3E2396307141%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2396307141&rft_id=info:pmid/32343797&rft_els_id=S2473952920313690&rfr_iscdi=true